Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2024-009690 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Ricardo DeAzevedo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Proto-Oncogene Proteins c-met. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Blockade of the immune checkpoints programmed death-1 (PD-1) and cytotoxic lymphocyte antigen 4 has improved outcomes for patients with hepatocellular carcinoma (HCC), yet most still fail to achieve objective clinical benefit. MET plays key roles in both HCC tumorigenesis and immunosuppressive conditioning; however, inhibition of MET causes upregulation of PD-ligand 1 (PD-L1) suggesting the use of these inhibitors in the context of PD-1 blockade. We sought to investigate across the Hepa1-6, HCA-1 and diethylnitrosamine (DEN) models of HCC whether the combination of more specific type I versus more pleiotropic type II MET inhibitors would confer superior outcomes in combination with PD-1 blockade. While MET inhibition demonstrated cooperativity with αPD-1 across all three models, the type I MET inhibitor capmatinib showed optimal activity in combination and statistically significantly outperformed the combination with the type II inhibitor cabozantinib in the αPD-1 refractory DEN model. In both HCA-1 and DEN HCC, the capmatinib and αPD-1 combination enhanced CD8 T cell frequency and activation state while limiting intratumoral myeloid immune suppression. In vitro studies of antigen-specific T cell activation reveal significantly less inhibition of effector cytokine production and proliferation by capmatinib versus by type II or type III MET inhibitors. These findings suggest significant potential for clinical HCC combination studies of type I MET inhibitors and PD-1 blockade where prior trials using type II inhibitors have yielded limited benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Immunology Program, The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA.
- Ionis Pharmaceuticals, Carlsbad, California, USA.
- Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA mcurran@mdanderson.org.
ORCID-Profile: Michael A Curran
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
DeAzevedo, R., Steiner, M., Turner, B. X., Liu, A., Newton, S., Schmidt, J., Fleming, R., Tolentino, A., Kaseb, A. O., & Curran, M. A. (2024). Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009690
Vancouver
DeAzevedo R, Steiner M, Turner BX, Liu A, Newton S, Schmidt J, et al. Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009690
BibTeX
@article{DeAzevedo2024,
author = {DeAzevedo, Ricardo and Steiner, Madeline and Turner, Broderick X and Liu, Arthur and Newton, Sherwin and Schmidt, Joanna and Fleming, Rachel and Tolentino, Angelica and Kaseb, Ahmed O and Curran, Michael A},
title = {Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2024-009690}
}
EUVIMED